CASSAVA SCIENCES INC PTIE Cash Flow

Cassava sciences inc (PTIE)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net loss
-4,422	-4,631	-3,792	-4,362	-5,756	-6,557	-8,298	-9,621	-11,328	-11,911	-12,015	-12,943	-11,798	-14,850	-16,845	-16,998	-17,357	-14,145	-11,784	-11,648	-11,519	-12,386	22,785	25,558	28,502	31,544	-3,265	-4,054	-3,884	-3,446	-2,043	-1,307	-2,376	-2,613	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Deferred program fee revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	41,119	8,343	9,110	9,875	10,641	10,897	10,897	10,897	10,897	0	0	0
Non-cash stock-based compensation
1,222	1,296	1,395	1,560	1,930	2,388	2,735	2,938	2,948	2,973	3,068	3,226	3,451	4,334	4,307	4,257	4,205	3,457	3,643	3,938	3,940	3,761	3,528	3,277	3,205	3,101	4,907	6,325	6,382	6,610	5,244	4,478	5,032	5,428	0	0	0
Depreciation and amortization
0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	157	140	145	163	0	0	0
Gain on sale of property and equipment
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash net interest income
-	-	-	-	-	-	-	-	-	2	7	7	7	8	0	0	0	-	-	-	-	-	-	-	-	10	12	-64	-202	-342	-513	-725	-888	-1,141	0	0	0
Changes in operating assets and liabilities:
Other current assets
125	23	109	19	28	49	-12	18	-14	-172	-172	-107	-177	-86	-176	-197	68	87	162	-282	-22	-26	-31	479	14	12	11	-92	-348	-105	294	11	5,509	214	0	0	0
Other non-current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-74	0	0	0
Accounts payable
113	159	-209	-368	74	-130	-163	304	-144	129	-343	308	-450	-711	165	-107	768	841	76	105	-173	-272	291	-75	62	84	24	-66	-136	-103	-49	-103	66	-643	0	0	0
Accrued development expense
144	621	415	179	225	-243	0	-32	10	372	-744	-609	-810	-867	102	193	611	869	305	116	-94	-616	-405	-240	-81	-288	-51	-33	-37	15	39	29	-16	656	0	0	0
Accrued compensation and benefits
10	-3	0	0	0	-	-	-	-	-26	-42	-625	-1,181	-288	-706	34	745	-29	-178	-147	-141	-60	674	668	-235	-141	-527	2	28	-62	292	-255	-414	-797	0	0	0
Other current liabilities
-1	9	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-24	-41	-34	-58	-72	-69	-60	-15	0	0	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12,751	-12,374	-11,048	-9,053	-8,068	-7,330	-7,973	-9,549	-8,440	-8,587	-7,797	-6,947	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-3,104	-2,514	-2,490	-3,196	-3,731	-4,770	-5,642	-6,357	-8,428	-8,237	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Cash flows from investing activities:
Purchases of property and equipment
-	18	0	0	0	-	-	-	-	-	-	-	-	75	76	0	0	195	196	196	196	80	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of property and equipment
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of marketable securities
-	-	-	-	-	-	-	-	-	399	2,494	3,043	3,043	4,141	2,046	2,396	3,345	3,847	3,845	4,047	3,347	2,598	3,849	4,047	5,097	6,644	12,287	15,274	18,770	20,768	0	0	0	-	-	-	-
Sales of marketable securities
-	-	-	-	-	-	-	-	-	400	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Maturities of marketable securities
-	-	-	-	-	-	-	-	-	2,100	0	0	0	-	-	-	-	-	-	-	-	3,850	4,050	5,100	6,650	12,300	15,287	28,790	37,790	38,390	39,103	34,300	27,498	62,400	0	0	0
Net cash provided (used in) investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	278	954	505	-192	9	-893	-943	1,172	122	974	1,474	5,656	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by / (used in) investing activities
100	-18	0	0	0	-	-	-	-	2,101	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Cash flows from financing activities:
Issuance costs from 2018 sale of common stock and warrants
-	60	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of common stock and warrants, net
-	-	-	-	-	14,098	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	379	643	643	584	524	0	0	0	-	-	-	-	9,042	0	0	0
Proceeds from exercise of common stock warrants, net
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	70	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	379	643	643	584	524	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by / (used in) financing activities
9,479	5,806	-132	12,140	12,140	14,098	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Net increase / (decrease) in cash and cash equivalents
6,475	3,274	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (decrease) / increase in cash and cash equivalents
-	-	-	-	-	-	-	-	-6,530	-6,136	-9,298	-10,559	-9,350	-14,684	-12,779	-11,726	-10,635	-9,291	-8,059	-8,223	-8,603	-7,998	-7,675	-6,970	-5,739	-767	-38,513	-27,475	-22,188	-23,789	16,531	16,190	18,885	68,346	0	0	0